Compare Krispy Kreme Inc (DNUT) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Krispy Kreme Inc vs Revvity Inc — how do they compare? Krispy Kreme Inc trades at $3.02 (market cap $521.37M), while Revvity Inc trades at $152.05 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 32.6× Krispy Kreme Inc's market cap, and Krispy Kreme Inc pays the higher dividend (3.47%). Which is the better fit depends on your goals — on Pluang, investors hold Krispy Kreme Inc for 45 Days and Revvity Inc for 12 Days on average.
| DNUT | RVTY | |
|---|---|---|
Market Cap | $521.37M | $16.98B |
Volume | 2,293,015 | 1,456,900 |
Sector | Consumer Staples | Health |
52-Week High | $4.70 | $157.36 |
52-Week Low | $2.87 | $82.26 |
Typical Hold Time | 45 Days | 12 Days |
Enterprise Value | $1.76B | $19.30B |
Dividend Yield | 3.47% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Krispy Kreme (DNUT) trades at $2.92, down 3.31% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $515.77M in 2025, with a negative net income margin of -33.88%, though revenue remains stable at $1.52B. Recent news highlights ongoing legal investigations into fiduciary duties of officers and directors, alongside seasonal product launches like the Pokémon doughnut collection.
The outlook is mixed; analyst consensus leans buy (50%) with a low P/S of 0.34 offering value, but profitability challenges and legal overhangs pose significant risks. Cash flow improved in 2025, yet high debt and negative ROE of -14.43% demand caution for stock investors seeking turnaround potential amid competitive pressures.
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving average signals and has beaten earnings estimates for three consecutive quarters. Recent developments include the launch of a CE-IVDR-certified T1D screening kit in Europe (Business Wire, 2026-09-24) and the acquisition of Human Cell Design to expand metabolic disease research tools (Business Wire, 2026-09-09).
The outlook is positive, supported by earnings momentum, strategic acquisitions, and analyst optimism. However, the stock trades at a premium valuation with a P/E of 73.15, and near-term risks include margin pressures in China and rich valuation limiting upside beyond consensus targets. Revenue stability but slight profit margin compression in 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
